Log in

NASDAQ:RLYPRelypsa Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$31.99
0.00 (0.00 %)
(As of 09/2/2016)
Add
Today's Range
$31.99
Now: $31.99
$31.99
50-Day Range N/A
52-Week Range
$10.26
Now: $31.99
$32.12
VolumeN/A
Average Volume2.93 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.
Read More
Relypsa logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:RLYP
CUSIPN/A
Phone+1-650-4219500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive RLYP News and Ratings via Email

Sign-up to receive the latest news and ratings for RLYP and its competitors with MarketBeat's FREE daily newsletter.

Relypsa (NASDAQ:RLYP) Frequently Asked Questions

Has Relypsa been receiving favorable news coverage?

News coverage about RLYP stock has trended somewhat negative on Saturday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Relypsa earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Relypsa.

What other stocks do shareholders of Relypsa own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relypsa investors own include Celgene (CELG), Royalty Pharma (RPRX), Synergy Pharmaceuticals (SGYP), Akorn (AKRX), Novavax (NVAX), Verastem (VSTM), Skechers USA (SKX), Sarepta Therapeutics (SRPT), Integrated Device Technology (IDTI) and Gilead Sciences (GILD).

What is Relypsa's stock symbol?

Relypsa trades on the NASDAQ under the ticker symbol "RLYP."

What is Relypsa's stock price today?

One share of RLYP stock can currently be purchased for approximately $31.99.

What is Relypsa's official website?

The official website for Relypsa is www.relypsa.com.

How can I contact Relypsa?

Relypsa's mailing address is 100 Cardinal Way, REDWOOD CITY, CA 94063-4755, United States. The biotechnology company can be reached via phone at +1-650-4219500.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.